Kimal

Kimal

Medical Equipment Manufacturing

Uxbridge, Middlesex 8,324 followers

At the heart of Kimal is a passion for delivering innovative solutions & exceeding our customers' expectations

About us

Kimal is an innovative manufacturer of customised procedure packs and vascular access devices to clinical departments in over 70 countries worldwide. The Company manufactures over 2 million procedure packs and vascular access devices every year for a range of specialities including: cardiology, radiology, pacing, laparoscopy, and cardiac surgery; and our unique, ground-breaking central venous catheter technology is helping to reduce patient risk in hospitals across the world. It all started in 1964 when Kimal began distributing innovative products for well-known medical companies. In fact, the Company was responsible for launching some of the 'healthcare firsts' in the UK, including: one of the first heart pacemakers; the Judkins catheter, which is still used in coronary angiography procedures today; the world's first hollow fibre dialyser, launching haemodialysis as we know it; the first US coronary angioplasty balloon technology, which is still used in percutaneous transluminal coronary angioplasty (PTCA) procedures today; and the first coronary stent, which is still used in percutaneous coronary interventions (PCI) today. In 1990, Kimal switched its focus from being a trusted distribution partner for large international companies to that of a trusted manufacturer and since launching the first cardiology procedure pack in the UK in the early nineties, the company has grown significantly. Today Kimal has direct sales offices in the UK, France, and the UAE, as well as manufacturing facilities in the UK and Egypt.

Industry
Medical Equipment Manufacturing
Company size
201-500 employees
Headquarters
Uxbridge, Middlesex
Type
Privately Held
Founded
1964
Specialties
Procedural Solutions and Vascular Access Devices

Locations

Employees at Kimal

Updates

  • We are proud to introduce our most recent addition to the Kimal Maternity portfolio: the ONIRY. Available for the first time in the UK, this technology will provide UK maternity healthcare providers with a high-precision diagnostic tool for previously undetected or misdiagnosed perineal tears. We’re excited for the significant impact this will have on improving health outcomes for new mothers and mitigating the risk of long-term health consequences. The ONIRY will be available in market from January 2025. #OASI #perinealhealth #maternity #ONIRY

  • Kimal was delighted to present our Maternity Portfolio at the Advances in Fetal Medicine Course held at Wembley Stadium, London. We were honored to have our partners, CELOX PPH™, join us to share their expertise.   We thoroughly enjoyed engaging with passionate delegates from around the world, keen to adopt the CELOX PPH Uterine Haemostatic Tamponade in their practices.   Key Statistics about CELOX PPH: ✅Achieves 100% haemostasis for grade 1 and 2 bleeding, up to 2,500 ml, in all deliveries. ✅Results in a 78% reduction in hysterectomy rates compared to the current standard of care.   A big thank you to everyone who visited us at the event!   If you couldn’t attend or didn’t get a chance to stop by our stand, don’t worry—we’re here to help! Feel free to reach out at 📧 maternity@kimal.com.   ✨ Together, we’re advancing maternal health. ✨ #KIMAL #CELOXPPH #MaternalHealth #PostpartumHemorrhage #FetalMedicine #HealthcareInnovation

    • No alternative text description for this image
    • No alternative text description for this image
    • No alternative text description for this image
    • No alternative text description for this image
  • View organization page for Kimal, graphic

    8,324 followers

    We're delighted to share the first picture of our #ChristmasTree in this year's Worcester Cathedral Christmas Tree Festival! Courtesy of Steve, Sean and Adelina, we've created a tree that celebrates our sixty year anniversary. Our Christmas Tree features a range of product components, 3D-printed baubles, and images of our key milestones over the past sixty years. #Christmas2024 #ChristmasDecor #KimalChristmas #DiamondAnniversary #Kimal60 #KimalTogether #60Anniversary #MedicalDevices

    • No alternative text description for this image
  • 📢 Kimal is Exhibiting at the 𝐈𝐕 𝐅𝐨𝐫𝐮𝐦 𝟐𝟎𝟐𝟒! We're excited to announce that the Kimal team will be attending the 12th Annual IV Forum 2024, hosted by the Infection Prevention Society (IPS). This year’s conference, "IV Access: Strategies for Success," will focus on key strategies to enhance patient safety and reduce risks associated with vascular access devices. 👉 Join us at 𝐒𝐭𝐚𝐧𝐝 𝟏𝟐 at the Birmingham Conference & Events Centre (BCEC) to discover how TauroLock™ can support infection prevention and catheter management. Our team will be available to discuss the latest research and how CRBSI prevention can be enhanced. 📍 Location: Birmingham Conference & Events Centre (BCEC) If you're unable to attend in person, don't worry! You can still reach out to us directly by emailing: taurolock@kimal.com for more information and insights. ✨ We look forward to connecting with healthcare professionals and sharing best practices to improve patient outcomes! Neil Garrard Pav Nijjar TauroPharm #IVAccess #IPSIVConf24 #InfectionPrevention #VascularAccess #Taurolidine

    • No alternative text description for this image
  • Join the Kimal Maternity team at 𝐏𝐑𝐎𝐌𝐏𝐓 𝐒𝐲𝐦𝐩𝐨𝐬𝐢𝐮𝐦 𝟐𝟎𝟐𝟒! We are honored to be attending this prestigious obstetrics event, centered on PROMPT’s compelling vision of “Making Childbirth Safer, Together”. We have the privilege of welcoming Professor Edvin Vaso to the Kimal stand, where he’ll share valuable insights on his first-hand experience of using CELOX PPH for the management of postpartum haemorrhage. As part of the symposium, he will be presenting his latest groundbreaking work on the management of PPH, including a prospective multicentre study. CELOX PPH provides a Fast & Effective solution, working independently of the patients clotting cascade and is transforming the standard of care for managing post-partum haemorrhage. Key Benefits of CELOX™ PPH: ✅Achieves 100% haemostasis for grade 1 and 2 bleeding (up to 2,500ml) ✅Clinical Efficacy: 95.6% success rate for grade 3 bleeding in vaginal deliveries ✅Reduced Hysterectomy Rates: 78% reduction compared to standard care We’re also proud to be joined by our CELOX™ partners, who will be on hand to provide additional expertise and answer your questions. ✨ Don’t miss this chance to connect, learn more and discuss a CELOX PPH trial for your hospital! 🗓️ Dates: 28th - 29th November 📍 Venue: Guildhall, Bath (High Street, Bath, BA1 5AW) We look forward to seeing you there! #PROMPTSymposium2024 #Kimal #IntrapartumCare #MaternalHealth #InnovationInCare

    • No alternative text description for this image
  • View profile for Omer Inbar, graphic

    Director of BD @ Tate' Medical | Co-Founder, Director | Healthcare Education Enthusiast | Father of 5

    Last week we finalized our product launch for central venous access at the Hospital Mexico, Costa Rica's largest hospital (around 700 beds). This important facility has just started using our central venous access catheters across multiple departments - ICU, emergency, surgery and others. For us it is fundamental to make sure that physicians & nurses are well educated about our products, best practices relating to patient management in our field and other empowering information so that we can ensure the best outcomes possible - for the caregivers and their patients. This would not be possible of course without the dedicated and meticulous work of our fantastic team - Andrea Bejarano, Emerson Morales from Tate' Medical Ltd. , Maria Diaz Alonso from Kimal, Leidy Vásquez from Capris Medica. The week was spent going, group by group, within the hospital training and demonstrating all clinical and practical aspects of the use of our products. As the requirements from the medical staff differ from department to department within an institution, it was important for our team to dedicate the time to create small groups of healthcare providers with, and across, each department. It is our "Educate to Elevate" philosophy in practice. A World Economic Forum executive focused on Central America said in a local Central America conference last year that: "The private sector has a central role in driving economic growth, and driving innovation and success of public-private partnerships. In Central America it is critical that governments, companies, and institutions work together." We feel fortunate to contribute our modest part to this partnership with the public institutions in Costa Rica and across Central America.

    • No alternative text description for this image
    • No alternative text description for this image
    • No alternative text description for this image
    • No alternative text description for this image
    • No alternative text description for this image
  • View organization page for Kimal, graphic

    8,324 followers

    🌟 We’re proud to partner with Professor Siobhan Quenby, one of the world’s leading researchers in miscarriages and the designer of the Quenby Cradle. 🌟 The 𝐐𝐮𝐞𝐧𝐛𝐲 𝐂𝐫𝐚𝐝𝐥𝐞 will be available in market from January 2025. It provides women experiencing miscarriages with a discreet, dignified way of collecting remains, providing emotional and physical comfort at a time when it’s most needed. Further updates will be available as we move towards launch. #MaternalHealth #InnovationInCare #Kimal #HealthcareInnovation #MedicalDevices #Healthcare #miscarriage

  • View organization page for Kimal, graphic

    8,324 followers

    🌟 Day 2 at 𝐁𝐈𝐂𝐒 𝐂𝐨𝐧𝐟𝐞𝐫𝐞𝐧𝐜𝐞 𝟐𝟎𝟐𝟒 – Supporting Innovation in Intrapartum Care! We’re proud to be at the British Intrapartum Care Society (BICS) Conference 2024 at the University of Edinburgh, showcasing the groundbreaking CELOX™ PPH Uterine Haemostatic Tamponade. A heartfelt thank you to everyone who attended Ms. Stacey Tyler's insightful presentation. This innovative solution is revolutionizing postpartum haemorrhage (PPH) management, and we’re proud to support its mission to transform maternal health outcomes across the UK. Why 𝐂𝐄𝐋𝐎𝐗™ 𝐏𝐏𝐇? ✅Rapid Control of PPH: Achieves 100% haemostasis for grade 1 and 2 bleeding (up to 2,500 ml). ✅Clinical Efficacy: Demonstrates a 95.6% success rate for grade 3 bleeding (up to 8,000 ml) in vaginal deliveries. ✅Reduced Hysterectomy Rates: Shows a 78% reduction in hysterectomy rates compared to standard care. ✅Ease of Use: Can be deployed quickly, does not require power and has no special storage conditions. Let’s work together to improve maternal health outcomes and reshape PPH management in the UK! CELOX PPH #BICS24 #CeloxPPH #Kimal #IntrapartumCare #MaternalHealth #InnovationInCare

    • No alternative text description for this image
    • No alternative text description for this image
    • No alternative text description for this image

Affiliated pages

Similar pages